ALT ID Week: "Clinical Performance of Assays to Predict Ciprofloxacin Resistance in Neisseria gonorrhoeae: Results from the MASTERMIND-RING Study," presented by Michael Satlin, MD, Associate Professor of Medicine, Weill Cornell Medicine. A R L G - Antibacterial Resistance Leadership Group

ALT ID Week: "Diagnostic Accuracy of Novel Microorganism- and Host-Directed Tests for Ventilator-Associated Pneumonia: Results from the MASTERMIND-Pneumonia Study," presented by Kimberly E. Hanson, MD, MHS, Professor of Medicine, University of Utah. A R L G - Antibacterial Resistance Leadership Group

ALT ID Week - Caroline B. Hall Lecture: "Antimicrobial Resistance: The Next Pandemic Is Already Here," presented by Pranita D. Tamma, MD, MHS, Professor of Pediatrics, University of Pennsylvania, Perelman School of Medicine. A R L G - Antibacterial Resistance Leadership Group

ALT Manuscript Published in NPJ Antimicrobials and Resistance, "Low-cost approaches for detecting antimicrobial resistance in bacterial infections in resource-limited settings: a scoping review," Roach D J, Krapp F, Bhat S, Flynn D B, Allan-Blitz L T, Bhattacharyya R P. David Roach, M D, M B A, M S c, Infectious Disease Attending Physician, Brigham and Women's Hospital, A R L G Fellow.

ALT Study Milestone - Enrollment Complete. MASTERMIND-RING: Master protocol for evaluating Multiple INfection Diagnostics - ResIstant Neisseria Gonorrhoeae. A R L G - Antibacterial Resistance Leadership Group

ALT Manuscript Published in the Journal of Infectious Diseases, "Genomic and Clinical Features Associated with Reduced Susceptibility to Cefiderocol and Cross-resistance to β-lactam/β-lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa," Egge S L, Kang D, Pouya N, et al. A R L G Antibacterial Resistance Leadership Group

ALT A R L G - Antibacterial Resistance Leadership Group alrg.org August 2026 Newsletter

ALT A R L G Member Spotlight: Chair, Gram-Positive Committee; Member, Innovations Working Group; Thomas Holland, MD, MSc-GH, Professor of Medicine, Infectious Diseases, Duke University. "Antimicrobial-resistant infections threaten our most vulnerable patients but can affect anybody. Advancing our ability to diagnose and treat these infections is one of the defining challenges of our time."

ALT Featured in JAMA Editorial, Podcast & Research Summary. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. Banerjee R, Komarow L, Li Y, et al. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G - Antibacterial Resistance Leadership Group. Study Milestone - Enrollment Closed. OPTIMIZE G N I: Optimization of Beta-lactam Dosing in Critically Ill Patients with Suspected or Documented Antimicrobial-Resistant Gram-Negative Infections with Cystatin C.

ALT A R L G Grand Rounds Recording: Innovations in Diagnostic Trials. Michael Satlin, MD, Weill Cornell Medicine; Sarah Doernberg, MD, MAS, UC San Francisco; Ritu Banerjee, MD, PhD, Vanderbilt University. Moderator: Robin Patel, MD, D(ABMM), FIDSA, FACP, F(AAM), FAAAS, Mayo Clinic. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G Member Spotlight: Associate Director, Laboratory Center, Sarah Doernberg, MD, MAS, Professor of Clinical Medicine, University of California, San Francisco. "Caring for patients with compromised immune systems, I witness the impact of antimicrobial-resistant infections frequently. High quality, informative clinical research that advances and informs the diagnosis and treatment of these infections is critical."

ALT A R L G DOOR Endpoint for Acute Bacterial Skin and Skin Structure Infections Featured in Open Forum Infectious Diseases. Editorial, "What's Behind DOOR Number 2? Recent Applications From Post-Hoc Analyses of Infectious Diseases Randomized Clinical Trials." A R L G - Antibacterial Resistance Leadership Group

ALT Manuscript Published in Open Forum Infectious Diseases, "Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections," Howard-Anderson J, Hamasaki T, Ge L, et al. DOOR Level infographic: A scale of 1 to 5 ranging from dark green (1 = best) to bright red (5 = worst). 1 = 0 Events, 2 = 1 Event, 3 = 2 Events, 4 = Greater than or equal to 3 Events, 5 = Death. *Events include: lack of improvement with the treatment; a different problem caused by the original infection; an unwelcome event which is life-threatening or leads to a longer hospitalization or significant disability.

ALT Study Milestone: Innovations QoL Second Study. Manuscript published in JAMA Network Open, "Comparing Patient and Clinician Perceptions of Health-Related Quality of Life in Urinary Tract Infections," Howard-Anderson J, Brown M, Korn R, et al. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G Clinical Trial Site Spotlight: a group photo of Dr. Natalie E. West & the Pulmonary Team at Johns Hopkins University next to a map of the northeast U.S. with a location marker pointing to Baltimore, Maryland.

ALT Congratulations! Vance Fowler, MD, MHS, Florence McAlister Distinguished Professor of Medicine, Professor of Molecular Genetics and Microbiology, Member in the Duke Clinical Research Institute. 2026 Hamao Umezawa Memorial Award, International Society of Antimicrobial Chemotherapy. A R L G - Antibacterial Resistance Leadership Group - a r l g .org

ALT ESCMID Postgraduate Course - Clinical trials in infectious diseases: from generating the initial idea to reporting final results and everything in between. A R L G - Antibacterial Resistance Leadership Group - a r l g .org

ALT Summary of Results PROOF Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants ARLG Antibacterial Resistance Leadership Group

ALT Summary of Results PROVIDE Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections ARLG Antibacterial Resistance Leadership Group